LegalAIClimate & EnergyDeveloper ToolsHR & TalentEnterprise SoftwareSaaSSocial & CommunityInsuranceBiotech & Life Sciences
Elad Gil's investment strategy centers on backing exceptional founders who are building companies in massive markets at their inflection points, often investing at the early stages. He seeks convex opportunities with significant upside, prioritizing strong unit economics, scalability, and a focus on solving real problems, with a recent emphasis on AI and infrastructure companies.
Deal activity increased 50% year-over-year (3 deals in the last 12 months). Average disclosed round size is $163.0M (across 11 rounds with reported amounts).
Portfolio
12
Fund Size
$3B
Top Stage
Series C
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Harvey | Series D | $200M | Mar 2026 |
 Base Power | Series C | $1B | Oct 2025 |
 Harvey AI | Series E | $300M | Jun 2025 |
 Decagon | Series C | $65M | Oct 2024 |
 Ashby | Series C | $30M | Jun 2024 |
 Neon | Series B | $46M | Aug 2023 |
 Metronome | Series A | $30M | Feb 2022 |
 Rossum | Series A | $100M | Oct 2021 |
| SSora | Series A | $14M | Aug 2021 |
 Clubhouse | Series C | — | Apr 2021 |
 AgentSync | Seed | $4.4M | Aug 2020 |
 Verge Genomics | Seed | $4M | Nov 2015 |
Top Co-Investors
Andreessen Horowitz4 shared
General Catalyst3 shared
Two Sigma Ventures2 shared
Lachy Groom2 shared
Sequoia Capital2 shared
Coatue Management2 shared
Conviction Partners2 shared
Kleiner Perkins2 shared
BOND2 shared
First Round Capital1 shared
DST Global1 shared
Tiger Global Management1 shared
LocalGlobe1 shared
Seedcamp1 shared
Miton1 shared
Menlo Ventures1 shared
Founders Fund1 shared
GGV Capital1 shared
Khosla Ventures1 shared
Snowflake1 shared
Last updated: 15 April 2026